Back to Search Start Over

Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases.

Authors :
Fitzgerald, Kathryn C
Mecoli, Christopher A
Douglas, Morgan
Harris, Samantha
Aravidis, Berna
Albayda, Jemima
Sotirchos, Elias S
Hoke, Ahmet
Orbai, Ana-Maria
Petri, Michelle
Christopher-Stine, Lisa
Baer, Alan N
Paik, Julie J
Adler, Brittany L
Tiniakou, Eleni
Timlin, Homa
Bhargava, Pavan
Newsome, Scott D
Venkatesan, Arun
Chaudhry, Vinay
Source :
Clinical Infectious Diseases; 2/1/2022, Vol. 74 Issue 3, p427-436, 10p
Publication Year :
2022

Abstract

Background People with autoimmune or inflammatory conditions taking immunomodulatory/suppressive medications may have higher risk of novel coronavirus disease 2019 (COVID-19). Chronic disease care has also changed for many patients, with uncertain downstream consequences. Methods We included participants with autoimmune or inflammatory conditions followed by specialists at Johns Hopkins. Participants completed periodic surveys querying comorbidities, disease-modifying medications, exposures, COVID-19 testing and outcomes, social behaviors, and disruptions to healthcare. We assessed whether COVID-19 risk is higher among those on immunomodulating or suppressive agents and characterized pandemic-associated changes to care and mental health. Results In total, 265 (5.6%) developed COVID-19 over 9 months of follow-up (April–December 2020). Patient characteristics (age, race, comorbidity, medications) were associated with differences in social distancing behaviors during the pandemic. Glucocorticoid exposure was associated with higher odds of COVID-19 in models incorporating behavior and other potential confounders (odds ratio [OR]: 1.43; 95% confidence interval [CI]: 1.08, 1.89). Other medication classes were not associated with COVID-19 risk. Diabetes (OR: 1.72; 95% CI: 1.08, 2.73), cardiovascular disease (OR: 1.68; 95% CI: 1.24, 2.28), and kidney disease (OR: 1.76; 95% CI: 1.04, 2.97) were associated with higher odds of COVID-19. Of the 2156 reporting pre-pandemic utilization of infusion, mental health or rehabilitative services, 975 (45.2%) reported disruptions therein, which disproportionately affected individuals experiencing changes to employment or income. Conclusions Glucocorticoid exposure may increase risk of COVID-19 in people with autoimmune or inflammatory conditions. Disruption to healthcare and related services was common. Those with pandemic-related reduced income may be most vulnerable to care disruptions. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10584838
Volume :
74
Issue :
3
Database :
Complementary Index
Journal :
Clinical Infectious Diseases
Publication Type :
Academic Journal
Accession number :
155241121
Full Text :
https://doi.org/10.1093/cid/ciab407